The DOI matches its OpenAlex record.
Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens
Abstract
The impact of 17beta-estradiol and antiestrogens on uterine cancer cells is poorly understood. The aim of this study was to determine the impact of 17beta-estradiol, 4-hydroxytamoxifen, raloxifene and ICI 182 780 on the cell proliferation of six uterine cancer cell lines: HeLa, HEC-1-A, KLE, RL-95-2, Ishikawa and EN-1078D. The effects of these compounds on the cell proliferation of the six uterine cancer cell lines were studied in the presence and absence of estrogens (phenol red and serum deprivation of sex steroids). In a general manner, 17beta-estradiol and 4-hydroxytamoxifen showed similarities in their effects whereas raloxifene showed a different pattern of cell proliferation (agonistic and antagonistic) and ICI 182 780 had antagonistic activity. In the presence and absence of estrogens, we observed that each cell line had diverse expression of ERalpha, ERbeta, GPR30 and REA. GPR30 mRNA expression was significantly reduced in a serum/phenol-free medium. REA mRNA expression was not influenced by the media. Results demonstrated the importance of removing phenol red and the use of deprived serum when studying uterine cancer cells in relationship with 17beta-estradiol and antiestrogens. The affinity of each compound to the binding of ERalpha and ERbeta was very similar with the exception of raloxifene that had a preference for ERalpha binding. Akt phosphorylation/activity was reduced in cells cultured in a phenol red- and steroid-free culture medium indicating that the presence of steroids in the culture media can influence the activity of this survival pathway. Our results suggest that the expression of ERalpha, ERbeta and GPR30 are influenced by sex steroids and might play a role in the response of cells to 17beta-estradiol and antiestrogens but are not the only factors involved in this process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The G-protein-coupled estrogen receptor GPER in health and disease
Prossnitz, E. R., & Barton, M. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.122 · Cited by 925
Resveratrol commonly displays hormesis: Occurrence and biomedical significance
Calabrese, E. J., Mattson, M. P., & Calabrese, V. (2010) · Human & Experimental Toxicology · doi:10.1177/0960327110383625 · Cited by 273
Prossnitz, E. R., & Arterburn, J. B. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009712 · Cited by 258
The Expression and Ovarian Steroid Regulation of Endometrial Micro-RNAs
Toloubeydokhti, T., Pan, Q., Luo, X., Bukulmez, O., & Chegini, N. (2008) · Reproductive Sciences · doi:10.1177/1933719108324132 · Cited by 83
RetractedKajta, M., Wójtowicz, A. K., Maćkowiak, M., & Lasoń, W. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2008.10.045 · Cited by 70
Metadata
- Authors
- Leblanc, K., Sexton, É., Parent, S., Bélanger, G., Déry, M.-C., Boucher, V., & Asselin, É.
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publishing
- Published
- 2007-02-01
- Volume
- 30
- Issue
- 2
- Pages
- 477-487
- ISSN
- 1019-6439 (ISSN-L)
- OpenAlex
- W2253171987
- Cited by
- 46
- References
- 0
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens. https://app.cochat.ai/papers/10.3892/ijo.30.2.477
- The paper
- Leblanc, K., Sexton, É., Parent, S., Bélanger, G., Déry, M.-C., Boucher, V., & Asselin, É. (2007). Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens. International Journal of Oncology. https://doi.org/10.3892/ijo.30.2.477
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.